CSF Biomarker May Support Lewy Body Diagnosis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

  • By

  • Henry Thomas

  • April 3, 2026

  • 2 min

Share

  • 1

    Elevated cerebrospinal fluid levels of DOPA decarboxylase may aid in diagnosing Lewy body disorders like Parkinson's disease and dementia with Lewy bodies.

  • 2

    CSF DDC concentrations were significantly higher in Lewy body disorders compared to cognitively healthy controls and Alzheimer’s disease.

  • 3

    Models using CSF DDC, age, and sex showed strong diagnostic performance for distinguishing Lewy body disorders from other conditions.

  • 4

    Higher CSF DDC levels correlated with specific clinical features in dementia with Lewy bodies, such as parkinsonian symptoms and visual hallucinations.

  • 5

    The study suggests CSF DDC may reflect dopaminergic neuronal dysfunction, but further research is needed to confirm its diagnostic utility.

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

FDA Approves At-Home Starting Dose for Lecanemab

Patients may begin lecanemab-irmb treatment at home through self-administration or administration by a caregiver, according to the FDA.

Diet-Dementia Link Varies by Biomarkers

Effects varied by which biomarker and diet were measured, and the study stops short of proving diet changes risk.